

MLA subsidiary MediVet in successful out of court settlement against competitor

Sydney, 7th July 2014: Human and animal healthcare company Medical Australia Limited (“MLA”, the “Company”) is pleased to announce that its US-based subsidiary, MediVet America LLC, has been successful in a legal action it brought against Vet-Stem Inc, with regard to claims against MediVet’s patented veterinary regenerative products.

A settlement was negotiated by MediVet in an out of court agreement. The terms of this settlement are confidential.

The action was brought by MediVet after false and misleading claims were made by Vet-Stem about MediVet's patented regenerative stem cell technology.

As well as the out of court settlement in MediVet's favour, the company is also pleased to confirm that its patented technologies have been independently tested and validated by both the University of Kentucky’s College of Medicine and Nexellcom Biosciences of Lawrence MA.

MediVet America CEO, Jeremy Delk stated: “This is a just outcome that serves to preserve our reputation as a provider of innovative and world leading regenerative therapies to the veterinary industry. Our partners can have every confidence in the integrity, efficacy and reliability of our stem cell technology, and this settlement re-affirms this.”

MLA Chief Operating Officer Darryl Ellis added: “There is considerable value in our patented technology and we will take all necessary measures to protect this value. We are now fully focused on continuing the roll-out of the MediVet technology throughout the US, Australia and other international markets.”

“MLA also looks forward to updating shareholders on the progress of its human and animal healthcare businesses over the coming months.”

- ENDS -

For more information contact:

Darryl Ellis

Chief Operating Officer

Medical Australia

Ph: +61 2 9466 5300

Media please contact: Ben Jarvis, Six Degrees Investor Relations: +61 413 150 448

ABOUT MEDICAL AUSTRALIA LIMITED

Medical Australia Limited (ASX: MLA) is a human and animal healthcare company engaged in the manufacture, distribution and sale of a broad range of medical and veterinary devices used by healthcare facilities, critical care services and veterinarians in global markets. The Company is a leader in Intravenous (IV) Medication Delivery Systems, Surgical Irrigation, Suction and Oxygen Therapy, Safety Sharps Collection and Reuse Prevention and specialised Diagnostic and Laboratory Equipment. Our products are used in three broad areas of healthcare, Human Health; Biological Collection, Processing and Laboratory; and Animal Health. Through the acquisition of MediVet Pty Ltd Medical Australia now has proprietary ownership of technology for regenerative medicine including stem cell therapy for domestic animals and the equine industry. Medical Australia’s animal health business is now represented in major countries and regions such as Canada, USA, Great Britain, Continental Europe, Australia and the Asia Pacific Region, including a 60.5% interest in MediVet America LLC.